Free Trial
→ Your free book is about to disappear (From Profits Run) (Ad)tc pixel Free BLGO Stock Alerts

BioLargo (BLGO) Financials

BioLargo logo
$0.07 +0.00 (+0.29%)
As of 10:36 AM Eastern
Compare
Annual Income Statements for BioLargo

Annual Income Statements for BioLargo

This table shows BioLargo's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -5.06 -7.84 -9.12 -10 -11 -8.43 -7.08 -4.47 -3.50 -2.40 -12
Consolidated Net Income / (Loss)		 -5.08 -8.07 -9.55 -11 -11 -9.70 -6.89 -5.13 -4.65 -4.35 -15
Net Income / (Loss) Continuing Operations		 -5.08 -8.07 -10 -9.45 -11 -9.70 -6.89 -5.13 -4.65 -4.36 -15
Total Pre-Tax Income 		-5.08 -8.07 -10 -9.53 -12 -9.81 -6.89 -5.20 -4.65 -4.35 -15
Total Operating Income		 -4.18 -4.93 -5.90 -6.41 -6.70 -7.58 -6.78 -5.39 -4.58 -4.33 -15
Total Gross Profit		 0.07 0.18 0.19 1.24 0.92 1.23 1.10 2.86 6.15 7.85 3.41
Total Revenue		 0.13 0.28 0.52 2.73 1.86 2.43 2.53 5.88 12 18 7.77
Operating Revenue		 0.13 0.28 0.52 2.73 1.86 2.43 2.53 5.88 12 18 7.77
Total Cost of Revenue		 0.06 0.11 0.96 1.49 0.95 1.20 1.43 3.03 6.08 9.93 4.36
Operating Cost of Revenue		 0.06 0.11 0.96 1.49 0.95 1.20 1.43 3.03 6.08 9.93 4.36
Total Operating Expenses		 4.25 5.11 6.09 6.41 7.61 8.81 7.88 8.25 11 12 18
Selling, General & Admin Expense		 3.55 3.71 4.43 5.31 6.14 7.47 6.17 6.73 8.06 9.30 12
Research & Development Expense		 0.68 1.38 1.63 1.72 1.47 1.34 1.37 1.32 2.28 2.88 2.59
Other Operating Expenses / (Income)		 - - - 0.62 - - - - - 0.00 3.89
Impairment Charge		 - - - - - - 0.34 0.20 0.39 0.00 0.01
Total Other Income / (Expense), net		 -0.90 -3.14 -3.72 -4.36 -4.81 -2.23 -0.12 0.20 -0.07 -0.02 -0.33
Interest Expense		 0.99 3.13 3.86 4.52 5.03 2.37 0.23 0.05 - 0.07 0.54
Interest & Investment Income		 - - - - - - - - -0.09 0.04 0.20
Other Income / (Expense), net		 0.10 -0.01 0.14 0.16 0.22 0.14 0.12 0.25 0.02 0.02 0.01
Net Income / (Loss) Attributable to Noncontrolling Interest		 -0.02 -0.23 -0.43 -0.48 -0.75 -1.27 0.19 -0.66 -1.14 -1.95 -3.41
Basic Earnings per Share		 ($0.06) ($0.09) ($0.10) ($0.09) ($0.08) ($0.05) ($0.03) ($0.02) ($0.01) ($0.01) ($0.04)
Weighted Average Basic Shares Outstanding		 84.11M 87.94M 98.94M 122.00M 152.09M 195.99M 247.20M 268.30M 285.96M 298.12M 306.95M
Weighted Average Diluted Shares Outstanding		 86.27M 94.95M 105.11M 143.10M 172.34M 238.78M 262.72M 283.19M 295.55M 301.30M 319.75M
Weighted Average Basic & Diluted Shares Outstanding		 86.27M 94.95M 105.11M 143.10M 172.34M 238.78M 262.72M 283.19M 295.55M 301.30M 319.75M

Quarterly Income Statements for BioLargo

This table shows BioLargo's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -0.73 -0.41 -0.44 -0.54 -1.01 -1.16 -1.19 -6.48 -2.95 -2.29 -2.77
Consolidated Net Income / (Loss)		 -1.02 -0.78 -0.78 -1.06 -1.73 -1.92 -1.88 -7.24 -4.14 -3.41 -4.00
Net Income / (Loss) Continuing Operations		 -1.02 -0.78 -0.78 -1.06 -1.75 -1.92 -1.88 -7.31 -4.08 -3.41 -4.00
Total Pre-Tax Income 		-1.03 -0.78 -0.78 -1.06 -1.73 -1.92 -1.88 -7.24 -4.14 -3.41 -4.00
Total Operating Income		 -1.01 -0.76 -0.89 -1.06 -1.62 -1.86 -1.80 -7.18 -4.01 -3.20 -3.73
Total Gross Profit		 2.09 2.25 2.14 1.72 1.75 1.49 1.42 0.37 0.13 0.46 0.68
Total Revenue		 4.37 4.76 5.01 4.35 3.65 3.27 2.78 1.10 0.62 1.12 1.25
Operating Revenue		 4.37 4.76 5.01 4.35 3.65 3.27 2.78 1.10 0.62 1.12 1.25
Total Cost of Revenue		 2.28 2.51 2.88 2.63 1.91 1.78 1.36 0.73 0.49 0.66 0.57
Operating Cost of Revenue		 2.28 2.51 2.88 2.63 1.91 1.78 1.36 0.73 0.49 0.66 0.57
Total Operating Expenses		 3.10 3.01 3.03 2.78 3.37 3.35 3.22 7.55 4.14 3.66 4.40
Selling, General & Admin Expense		 2.27 2.23 2.40 2.09 2.58 2.52 2.69 3.09 3.43 2.76 3.32
Research & Development Expense		 0.44 0.78 0.62 0.69 0.79 0.79 0.54 0.62 0.65 0.91 1.09
Total Other Income / (Expense), net		 -0.03 -0.01 0.11 0.00 -0.12 -0.06 -0.08 -0.06 -0.13 -0.20 -0.27
Interest Expense		 - - - 0.01 - 0.09 0.12 0.14 - 0.19 0.29
Interest & Investment Income		 - -0.01 -0.00 0.01 0.04 0.03 0.04 0.08 0.27 0.07 0.01
Other Income / (Expense), net		 -0.01 0.00 0.11 0.00 -0.10 0.01 0.00 0.00 - -0.09 0.00
Net Income / (Loss) Attributable to Noncontrolling Interest		 -0.29 -0.37 -0.34 -0.52 -0.72 -0.77 -0.69 -0.77 -1.19 -1.12 -1.23
Basic Earnings per Share		 - $0.00 $0.00 $0.00 ($0.01) $0.00 $0.00 ($0.02) ($0.01) ($0.01) ($0.01)
Weighted Average Basic Shares Outstanding		 285.96M 294.31M 296.44M 300.49M 298.12M 301.27M 303.20M 308.97M 306.95M 318.70M 320.98M
Weighted Average Diluted Shares Outstanding		 295.55M 296.84M 300.62M 301.18M 301.30M 302.84M 308.99M 313.76M 319.75M 320.88M 328.73M
Weighted Average Basic & Diluted Shares Outstanding		 295.55M 296.84M 300.62M 301.18M 301.30M 302.84M 308.99M 313.76M 319.75M 320.88M 328.73M

Annual Cash Flow Statements for BioLargo

This table details how cash moves in and out of BioLargo's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 1.61 0.15 -0.92 -0.34 0.29 0.06 0.25 0.89 2.49 -2.13 -0.18
Net Cash From Operating Activities		 -1.88 -3.72 -4.28 -3.89 -4.42 -4.15 -3.94 -2.76 -2.37 -3.21 -8.30
Net Cash From Continuing Operating Activities		 -1.88 -3.72 -4.89 -3.89 -4.44 -4.15 -3.94 -2.76 -2.37 -3.21 -8.30
Net Income / (Loss) Continuing Operations		 -5.08 -8.07 -9.55 -11 -11 -9.70 -6.89 -5.13 -4.65 -4.35 -15
Consolidated Net Income / (Loss)		 -5.08 -8.07 -9.55 -11 -11 -9.70 -6.89 -5.13 -4.65 -4.35 -15
Depreciation Expense		 0.01 0.02 0.03 0.05 0.07 0.06 0.02 0.05 0.10 0.16 0.15
Amortization Expense		 0.81 2.61 3.06 2.77 3.38 1.62 0.12 0.02 0.17 0.10 0.46
Non-Cash Adjustments To Reconcile Net Income		 2.50 1.92 2.21 3.82 3.55 3.80 2.57 2.56 2.93 2.42 7.29
Changes in Operating Assets and Liabilities, net		 -0.13 -0.19 -0.04 0.17 0.01 0.07 0.25 -0.25 -0.92 -1.54 -1.00
Net Cash From Investing Activities		 0.00 -0.06 -0.03 -0.06 -0.04 -0.12 -0.03 -0.27 -0.48 -1.32 0.44
Net Cash From Continuing Investing Activities		 0.00 -0.06 -0.03 -0.06 -0.04 -0.12 -0.03 -0.27 -0.48 -1.32 0.44
Purchase of Property, Plant & Equipment		 0.00 -0.06 -0.03 -0.06 -0.04 -0.02 -0.02 -0.27 -0.48 -1.24 -0.05
Sale of Property, Plant & Equipment		 - - - - - - - - - 0.00 0.48
Other Investing Activities, net		 - - - - - - - - 0.00 -0.08 0.00
Net Cash From Financing Activities		 3.53 3.97 3.37 3.64 4.47 4.34 4.23 3.96 4.66 4.44 8.22
Net Cash From Continuing Financing Activities		 3.53 3.97 3.37 3.64 4.76 4.34 4.23 3.96 5.46 2.39 7.69
Repayment of Debt		 -0.02 0.00 -0.05 -0.24 -1.09 -0.06 -0.87 -0.03 0.04 -0.01 0.02
Issuance of Debt		 0.00 0.80 0.25 0.83 0.83 0.77 0.00 0.10 0.00 0.86 1.26
Issuance of Preferred Equity		 - - - - - - 0.00 0.23 1.58 0.00 2.15
Issuance of Common Equity		 0.75 0.00 1.26 1.84 0.13 3.63 4.93 3.62 2.15 0.59 2.03
Other Financing Activities, net		 2.80 3.17 1.95 1.21 4.90 0.00 0.16 0.04 1.69 0.95 2.23
Cash Interest Paid		 0.01 0.01 0.01 0.05 0.20 0.12 0.10 0.04 0.06 0.03 0.34
Cash Income Taxes Paid		 0.00 0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for BioLargo

This table details how cash moves in and out of BioLargo's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 1.30 0.80 0.43 -1.92 -1.44 -1.26 0.91 1.08 -1.17 0.24 -1.93
Net Cash From Operating Activities		 -0.00 0.48 -0.15 -1.62 -1.92 -1.83 -2.12 -2.76 -1.59 -2.92 -3.06
Net Cash From Continuing Operating Activities		 -0.00 0.48 -0.15 -1.62 -1.92 -1.83 -2.12 -2.76 -1.59 -2.92 -3.06
Net Income / (Loss) Continuing Operations		 -1.02 -0.78 -0.78 -1.06 -1.73 -1.92 -1.88 -7.24 -4.14 -3.41 -4.00
Consolidated Net Income / (Loss)		 -1.02 -0.78 -0.78 -1.06 -1.73 -1.92 -1.88 -7.24 -4.14 -3.41 -4.00
Depreciation Expense		 0.01 0.04 0.04 0.04 0.04 0.04 0.04 0.03 0.03 0.03 0.03
Amortization Expense		 0.08 0.01 0.04 0.03 0.03 0.07 0.08 0.11 0.19 0.14 0.15
Non-Cash Adjustments To Reconcile Net Income		 1.14 0.58 0.58 0.32 0.94 0.72 0.67 4.68 1.24 0.71 0.79
Changes in Operating Assets and Liabilities, net		 -0.21 0.63 -0.03 -0.95 -1.19 -0.74 -1.03 -0.33 1.09 -0.40 -0.03
Net Cash From Investing Activities		 -0.15 -0.86 -0.36 -0.04 -0.06 0.00 0.19 0.26 -0.01 -0.03 -0.16
Net Cash From Continuing Investing Activities		 -0.15 -0.86 -0.36 -0.04 -0.06 0.00 0.19 0.26 -0.01 -0.03 -0.16
Purchase of Property, Plant & Equipment		 -0.15 -0.86 -0.36 -0.04 0.03 0.00 - -0.03 -0.01 -0.03 -0.16
Net Cash From Financing Activities		 0.76 1.08 1.00 0.76 1.59 0.87 2.83 3.57 0.95 3.19 1.28
Net Cash From Continuing Financing Activities		 1.56 1.08 1.00 -0.23 0.54 0.57 2.83 3.57 0.42 3.19 1.28
Repayment of Debt		 0.12 -0.01 -0.00 -0.00 -0.00 -0.00 -0.01 -0.01 0.04 -0.01 -0.14
Issuance of Debt		 - 0.00 - - 0.86 0.59 0.72 - -0.05 2.40 1.00
Issuance of Common Equity		 -0.25 0.53 0.64 -0.82 0.25 -0.02 - - 1.73 0.26 0.39
Other Financing Activities, net		 1.69 0.56 0.36 0.59 -0.57 0.00 2.12 1.43 -1.31 0.55 0.03
Cash Interest Paid		 0.02 0.01 0.00 -0.00 0.02 0.04 - 0.21 0.10 0.13 0.22

Annual Balance Sheets for BioLargo

This table presents BioLargo's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 1.91 2.11 1.50 3.19 3.62 4.94 3.02 4.86 8.21 11 8.31
Total Current Assets		 1.89 2.02 1.16 0.96 1.07 1.51 1.80 3.15 6.36 7.14 5.11
Cash & Equivalents		 1.76 1.91 0.99 0.66 0.66 0.72 0.96 1.85 3.54 3.55 3.88
Accounts Receivable		 0.04 0.07 0.09 0.26 0.36 0.48 0.51 1.06 2.61 3.17 0.62
Inventories, net		 0.04 0.03 0.05 0.03 0.02 0.28 0.24 0.12 0.15 0.33 0.31
Prepaid Expenses		 0.05 0.00 0.02 0.02 0.04 0.03 0.09 0.12 0.06 0.09 0.31
Plant, Property, & Equipment, net		 0.00 0.06 0.11 0.13 0.10 0.06 0.06 0.29 0.66 1.74 1.64
Plant, Property & Equipment, gross		 - - 0.11 - 0.10 - - 0.29 - - 1.64
Total Noncurrent Assets		 0.02 0.04 0.23 2.10 2.46 3.38 1.16 1.42 1.18 1.55 1.55
Noncurrent Note & Lease Receivables		 - - - - - - - - 0.00 0.45 0.42
Other Noncurrent Operating Assets		 0.02 0.04 0.23 0.21 0.57 1.16 1.11 1.39 1.16 1.09 1.13
Total Liabilities & Shareholders' Equity		 1.91 2.11 1.50 3.19 3.62 4.94 3.02 4.86 8.21 11 8.31
Total Liabilities		 0.77 2.88 4.91 4.31 5.80 5.18 2.09 2.85 4.00 4.46 6.79
Total Current Liabilities		 0.46 1.15 4.22 2.49 4.35 3.54 1.37 1.58 2.71 2.65 5.06
Short-Term Debt		 0.00 0.61 5.25 2.20 5.06 2.33 0.31 0.00 0.30 0.55 1.48
Accounts Payable		 0.32 0.20 0.22 0.50 1.00 1.05 1.35 2.12 1.49 1.81 4.01
Customer Deposits		 0.14 - - - - - - - 0.12 - 0.19
Current Deferred Revenue		 - - - - 0.04 0.05 0.09 0.02 - 0.00 0.28
Other Current Liabilities		 0.00 0.26 -1.26 -0.21 0.13 0.11 0.10 0.10 0.41 0.19 0.31
Total Noncurrent Liabilities		 0.31 1.73 0.69 1.82 0.93 1.63 0.72 1.27 1.29 1.81 1.72
Long-Term Debt		 3.25 5.25 1.54 1.29 - 0.51 0.37 0.50 0.29 0.53 0.60
Capital Lease Obligations		 - - - 0.00 - - - 0.77 - 0.36 0.86
Other Noncurrent Operating Liabilities		 -2.94 -3.52 0.00 0.53 0.93 1.13 0.35 - 1.00 0.92 0.26
Total Equity & Noncontrolling Interests		 1.14 -0.77 -3.41 -1.12 -2.18 -0.24 0.93 2.01 4.20 6.06 1.53
Total Preferred & Common Equity		 0.35 -1.33 -4.10 -1.50 -2.15 3.86 4.65 4.88 6.84 8.85 4.04
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 0.35 -1.33 -4.10 -1.50 -2.15 3.86 4.65 4.88 6.84 8.85 4.04
Common Stock		 84 91 97 110 121 136 144 149 154 159 166
Retained Earnings		 -84 -92 -101 -112 -123 -132 -139 -144 -147 -150 -161
Accumulated Other Comprehensive Income / (Loss)		 -0.04 -0.08 -0.06 -0.09 -0.10 -0.10 -0.12 -0.15 -0.28 -0.18 -0.21
Noncontrolling Interest		 0.79 0.55 0.70 0.37 -0.03 -4.09 -3.72 -2.87 -2.64 -2.80 -2.52

Quarterly Balance Sheets for BioLargo

This table presents BioLargo's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 6.55 9.82 10 10 11 12 9.13 8.57 6.67
Total Current Assets		 4.69 7.18 7.11 7.39 7.22 9.19 5.78 5.45 3.50
Cash & Equivalents		 3.04 4.34 4.77 3.88 2.56 3.47 4.55 4.12 2.19
Accounts Receivable		 1.45 2.47 2.10 3.21 4.21 1.74 0.76 0.73 0.72
Inventories, net		 0.12 0.25 0.18 0.24 0.37 0.44 0.41 0.29 0.30
Prepaid Expenses		 0.07 0.12 0.07 0.07 0.08 0.05 0.06 0.30 0.28
Plant, Property, & Equipment, net		 0.60 1.49 1.81 1.81 1.70 1.66 1.66 1.64 1.77
Plant, Property & Equipment, gross		 - - 1.81 1.81 1.70 1.66 1.66 - 1.77
Total Noncurrent Assets		 1.26 1.16 1.13 1.10 1.59 1.65 1.69 1.40 1.40
Noncurrent Note & Lease Receivables		 - - - - 0.52 0.59 0.48 0.31 0.36
Other Noncurrent Operating Assets		 1.24 1.14 1.11 1.09 1.06 1.04 1.19 1.09 1.04
Total Liabilities & Shareholders' Equity		 6.55 9.82 10 10 11 12 9.13 8.57 6.67
Total Liabilities		 2.73 4.67 4.16 4.32 5.42 6.44 5.92 8.75 9.40
Total Current Liabilities		 1.74 3.40 3.01 3.20 3.37 4.08 3.45 4.93 4.77
Short-Term Debt		 0.07 0.23 0.00 0.00 0.81 1.12 1.12 1.51 1.42
Accounts Payable		 0.89 1.74 3.94 4.40 3.51 4.04 2.92 2.59 4.12
Customer Deposits		 0.12 0.23 - - 0.09 - 0.08 - 0.08
Current Deferred Revenue		 0.00 - 0.09 0.02 - - - 0.32 0.05
Other Current Liabilities		 0.10 1.42 0.11 0.11 0.19 0.19 0.23 0.33 0.34
Total Noncurrent Liabilities		 0.99 1.27 1.15 1.12 2.05 2.36 2.46 3.82 4.63
Long-Term Debt		 0.29 0.28 0.18 0.18 0.81 1.17 1.20 2.78 3.69
Capital Lease Obligations		 - - 0.97 0.94 0.90 0.87 0.97 0.23 0.75
Other Noncurrent Operating Liabilities		 0.70 0.99 - - 0.34 0.32 0.30 0.81 0.20
Total Equity & Noncontrolling Interests		 3.82 5.15 5.89 5.98 5.09 6.06 3.22 -0.19 -2.73
Total Preferred & Common Equity		 7.07 8.12 6.00 8.58 7.61 8.76 6.58 1.79 -1.85
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 7.07 8.12 6.00 8.58 7.61 8.76 6.58 1.79 -1.85
Common Stock		 154 156 154 157 158 161 165 166 165
Retained Earnings		 -146 -148 -148 -148 -151 -152 -158 -164 -166
Accumulated Other Comprehensive Income / (Loss)		 -0.16 -0.18 -0.24 -0.23 -0.20 -0.20 -0.20 -0.21 -0.21
Noncontrolling Interest		 -3.25 -2.97 -0.11 -2.60 -2.52 -2.70 -3.37 -1.97 -0.88

Annual Metrics And Ratios for BioLargo

This table displays calculated financial ratios and metrics derived from BioLargo's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 89,915,980.00 102,364,539.00 132,292,528.00 163,916,660.00 222,395,857.00 257,726,382.00 275,417,050.00 289,500,358.00 301,179,163.00 313,762,657.00
DEI Adjusted Shares Outstanding		 0.00 89,915,980.00 102,364,539.00 132,292,528.00 163,916,660.00 222,395,857.00 257,726,382.00 275,417,050.00 289,500,358.00 301,179,163.00 313,762,657.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -0.09 -0.09 -0.08 -0.07 -0.04 -0.03 -0.02 -0.01 -0.01 -0.04
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 14.38% 120.33% 83.56% 428.68% -31.78% 30.68% 4.07% 132.48% 107.85% 45.37% -56.32%
EBITDA Growth		 3.25% 28.94% -15.07% -28.86% 11.66% -89.99% -13.02% 22.10% 15.71% 5.21% -251.00%
EBIT Growth		 -20.37% -21.14% -16.40% -8.65% -3.58% -14.94% 10.56% 22.79% 11.38% 5.33% -244.20%
NOPAT Growth		 -23.30% -18.02% -19.48% -8.75% -4.43% -13.25% 10.62% 20.48% 15.03% 5.44% -242.99%
Net Income Growth		 -35.77% -59.04% -18.24% -12.04% -6.96% 15.21% 28.93% 25.56% 9.43% 6.48% -249.41%
EPS Growth		 -20.00% -50.00% -11.11% 10.00% 11.11% 37.50% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 -9.58% -97.57% -15.13% 9.17% -13.65% 6.06% 5.22% 29.85% 14.37% -35.56% -158.80%
Free Cash Flow Firm Growth		 -142.69% 31.42% 38.02% -87.39% 17.16% -62.03% 51.34% -44.32% 6.76% -30.50% -22.48%
Invested Capital Growth		 984.38% 21.19% -51.61% 11.05% -48.45% 107.26% -93.21% 498.39% 119.68% 141.78% -97.82%
Revenue Q/Q Growth		 -10.27% 4.11% 34.41% 0.00% 0.00% 0.00% -21.57% 47.06% 22.84% -3.87% -28.12%
EBITDA Q/Q Growth		 23.15% 15.69% -30.81% -214.58% -201.37% -72.70% 21.52% -35.03% 9.43% -21.49% -17.67%
EBIT Q/Q Growth		 4.10% -7.09% -6.27% 0.00% 0.00% -24.56% 21.56% -34.93% 7.68% -19.27% -18.32%
NOPAT Q/Q Growth		 1.77% -6.86% -5.33% 0.00% 0.00% -4.18% 2.92% 6.05% 8.20% -16.39% -19.21%
Net Income Q/Q Growth		 -3.58% -15.94% -1.31% 0.00% 0.00% 0.00% 2.85% 6.94% 7.70% -19.59% -18.86%
EPS Q/Q Growth		 14.29% -12.50% -11.11% 10.00% -14.29% 16.67% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -14.67% -11.33% -7.19% 8.67% -9.97% 8.88% -3.66% 26.89% -1.85% -148.14% 3.78%
Free Cash Flow Firm Q/Q Growth		 -86.54% 42.68% 20.67% -295.84% -41.66% -47.99% 25.16% -65.39% 20.89% -90.42% 16.95%
Invested Capital Q/Q Growth		 1,064.09% -8.92% -43.15% 419.94% -71.14% -16.35% -90.89% 0.00% -3.15% 109.18% -91.73%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 51.35% 62.34% 37.40% 45.53% 49.22% 50.49% 43.58% 48.56% 50.32% 44.17% 43.86%
EBITDA Margin		 -2,557.47% -824.81% -517.05% -126.03% -163.19% -237.25% -257.65% -86.34% -35.01% -22.83% -183.48%
Operating Margin		 -3,277.49% -1,755.52% -1,142.64% -235.04% -359.81% -311.80% -267.80% -91.60% -37.45% -24.36% -191.31%
EBIT Margin		 -3,199.79% -1,759.21% -1,115.50% -229.25% -348.09% -306.17% -263.14% -87.39% -37.26% -24.26% -191.23%
Profit (Net Income) Margin		 -3,979.43% -2,872.35% -1,850.19% -392.08% -614.72% -398.85% -272.38% -87.22% -38.00% -24.45% -195.61%
Tax Burden Percent		 100.00% 100.00% 93.09% 112.27% 99.45% 98.87% 100.00% 98.79% 100.00% 100.00% 100.00%
Interest Burden Percent		 124.37% 163.28% 178.18% 152.33% 177.57% 131.76% 103.51% 101.03% 102.00% 100.77% 102.29%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -251.52% -119.02% -174.91% -276.38% -361.95% -392.18% -486.63% -871.36% -270.32% -108.84% -516.44%
ROIC Less NNEP Spread (ROIC-NNEP)		 -523.95% -289.08% -296.72% -435.96% -591.13% -563.67% -829.98% -740.56% -195.24% -52.71% -246.93%
Return on Net Nonoperating Assets (RNNOA)		 -1,103.99% -4,231.72% 631.79% 748.40% 1,054.65% 1,195.49% -1,488.73% 522.72% 120.70% 24.09% 115.78%
Return on Equity (ROE)		 -1,355.50% -4,350.75% 456.88% 472.02% 692.70% 803.31% -1,975.36% -348.64% -149.62% -84.75% -400.66%
Cash Return on Invested Capital (CROIC)		 -222.85% -138.18% -105.35% -286.85% -298.01% -461.99% -312.06% -1,014.09% -345.19% -191.80% -324.98%
Operating Return on Assets (OROA)		 -376.09% -245.85% -319.00% -267.21% -190.36% -173.91% -167.23% -130.49% -69.77% -46.09% -157.77%
Return on Assets (ROA)		 -467.72% -401.41% -529.11% -457.00% -336.17% -226.56% -173.11% -130.24% -71.16% -46.45% -161.38%
Return on Common Equity (ROCE)		 182.95% 11,409.59% 593.53% 583.26% 765.27% -567.14% -24,086.35% -1,128.70% -282.29% -129.67% -681.31%
Return on Equity Simple (ROE_SIMPLE)		 -1,443.18% 609.31% 232.63% 714.97% 531.35% -251.43% -148.16% -105.21% -67.91% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -2.93 -3.45 -4.13 -4.49 -4.69 -5.31 -4.74 -3.77 -3.21 -3.03 -10
NOPAT Margin		 -2,294.24% -1,228.86% -799.85% -164.53% -251.86% -218.26% -187.46% -64.12% -26.21% -17.05% -133.92%
Net Nonoperating Expense Percent (NNEP)		 272.43% 170.06% 121.81% 159.58% 229.18% 171.49% 343.35% -130.80% -75.08% -56.13% -269.51%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -66.92% -40.45% -269.25%
Cost of Revenue to Revenue		 48.65% 37.66% 186.24% 54.47% 50.78% 49.51% 56.42% 51.44% 49.68% 55.83% 56.14%
SG&A Expenses to Revenue		 2,783.72% 1,321.35% 858.33% 194.79% 329.93% 307.28% 243.86% 114.40% 65.89% 52.32% 151.55%
R&D to Revenue		 536.56% 491.61% 315.89% 63.01% 79.10% 55.02% 54.01% 22.42% 18.66% 16.21% 33.39%
Operating Expenses to Revenue		 3,328.84% 1,817.85% 1,180.04% 235.04% 409.03% 362.29% 311.38% 140.16% 87.77% 68.53% 235.17%
Earnings before Interest and Taxes (EBIT)		 -4.08 -4.95 -5.76 -6.25 -6.48 -7.45 -6.66 -5.14 -4.56 -4.31 -15
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -3.26 -2.32 -2.67 -3.44 -3.04 -5.77 -6.52 -5.08 -4.28 -4.06 -14
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 122.62 0.00 0.00 0.00 0.00 7.61 11.98 11.31 7.25 6.47 14.58
Price to Tangible Book Value (P/TBV)		 122.62 0.00 0.00 0.00 0.00 17.20 11.98 11.31 7.25 6.47 14.58
Price to Revenue (P/Rev)		 338.10 279.32 78.42 12.56 20.00 12.08 22.03 9.38 4.06 3.22 7.59
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 17.30 26.11 30.51 21.93 47.23 14.97 416.94 69.70 27.01 13.28 637.99
Enterprise Value to Revenue (EV/Rev)		 355.91 295.35 91.01 13.74 22.36 11.24 20.43 8.79 3.60 2.94 7.07
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 2.84 -7.61 -1.99 -3.11 -2.32 -12.09 0.73 0.63 0.14 0.24 1.53
Long-Term Debt to Equity		 2.84 -6.82 -0.45 -1.15 0.00 -2.16 0.39 0.63 0.07 0.15 0.56
Financial Leverage		 2.11 14.64 -2.13 -1.72 -1.78 -2.12 1.79 -0.71 -0.62 -0.46 -0.47
Leverage Ratio		 2.90 10.84 -0.86 -1.03 -2.06 -3.55 11.41 2.68 2.10 1.82 2.48
Compound Leverage Factor		 3.60 17.70 -1.54 -1.57 -3.66 -4.67 11.81 2.70 2.14 1.84 2.54
Debt to Total Capital		 73.99% 115.13% 200.89% 147.50% 175.59% 109.02% 42.19% 38.73% 12.29% 19.20% 60.49%
Short-Term Debt to Total Capital		 0.00% 11.98% 155.34% 92.85% 175.59% 89.56% 19.45% 0.00% 6.26% 7.36% 38.27%
Long-Term Debt to Total Capital		 73.99% 103.15% 45.55% 54.65% 0.00% 19.46% 22.74% 38.73% 6.03% 11.83% 22.22%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 18.00% 10.90% 20.57% 15.78% -0.94% -157.12% -230.48% -87.36% -55.15% -37.29% -65.15%
Common Equity to Total Capital		 8.02% -26.03% -121.46% -63.28% -74.65% 148.10% 288.29% 148.63% 142.85% 118.09% 104.66%
Debt to EBITDA		 -0.99 -2.53 -2.54 -1.01 -1.67 -0.49 -0.10 -0.25 -0.14 -0.35 -0.16
Net Debt to EBITDA		 -0.45 -1.70 -2.17 -0.82 -1.45 -0.36 0.05 0.12 0.69 0.52 0.11
Long-Term Debt to EBITDA		 -0.99 -2.26 -0.58 -0.38 0.00 -0.09 -0.06 -0.25 -0.07 -0.22 -0.06
Debt to NOPAT		 -1.11 -1.70 -1.64 -0.78 -1.08 -0.54 -0.14 -0.34 -0.18 -0.47 -0.22
Net Debt to NOPAT		 -0.51 -1.14 -1.40 -0.63 -0.94 -0.39 0.07 0.16 0.93 0.70 0.15
Long-Term Debt to NOPAT		 -1.11 -1.52 -0.37 -0.29 0.00 -0.10 -0.08 -0.34 -0.09 -0.29 -0.08
Altman Z-Score		 -34.04 -51.67 -104.57 -50.54 -50.38 -38.98 -54.69 -31.64 -17.47 -11.35 -26.91
Noncontrolling Interest Sharing Ratio		 113.50% 362.24% -29.91% -23.57% -10.48% 170.60% -1,119.34% -223.74% -88.67% -53.00% -70.05%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.11 1.75 0.27 0.38 0.24 0.42 1.31 2.00 2.35 2.70 1.01
Quick Ratio		 3.92 1.71 0.26 0.37 0.23 0.34 1.07 1.85 2.27 2.54 0.89
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -5.85 -4.01 -2.49 -4.66 -3.86 -6.25 -3.04 -4.39 -4.09 -5.34 -6.54
Operating Cash Flow to CapEx		 0.00% -6,008.16% -14,772.41% -6,708.62% -12,634.29% -18,060.87% -18,747.62% -1,019.19% -494.77% -259.60% 0.00%
Free Cash Flow to Firm to Interest Expense		 -5.88 -1.28 -0.64 -1.03 -0.77 -2.64 -13.00 -82.85 0.00 -75.25 -12.12
Operating Cash Flow to Interest Expense		 -1.89 -1.19 -1.11 -0.86 -0.88 -1.76 -16.82 -52.11 0.00 -45.15 -15.36
Operating Cash Flow Less CapEx to Interest Expense		 -1.89 -1.21 -1.12 -0.87 -0.89 -1.77 -16.91 -57.23 0.00 -62.55 -14.56
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.12 0.14 0.29 1.17 0.55 0.57 0.64 1.49 1.87 1.90 0.83
Accounts Receivable Turnover		 5.42 5.14 6.37 15.54 6.08 5.80 5.08 7.46 6.65 6.15 4.11
Inventory Turnover		 1.97 2.95 21.73 37.15 45.00 8.22 5.51 16.77 44.51 41.10 13.62
Fixed Asset Turnover		 0.00 0.00 6.13 23.22 16.84 31.38 41.83 33.82 25.77 14.79 4.59
Accounts Payable Turnover		 0.15 0.40 4.53 4.10 1.26 1.18 1.19 1.75 3.37 6.01 1.89
Days Sales Outstanding (DSO)		 67.30 71.04 57.29 23.48 60.02 62.96 71.89 48.91 54.85 59.33 88.91
Days Inventory Outstanding (DIO)		 185.09 123.90 16.80 9.83 8.11 44.41 66.20 21.76 8.20 8.88 26.80
Days Payable Outstanding (DPO)		 2,410.87 905.09 80.54 89.04 289.10 309.98 306.34 208.97 108.31 60.69 193.26
Cash Conversion Cycle (CCC)		 -2,158.48 -710.15 -6.45 -55.73 -220.98 -202.61 -168.25 -138.29 -45.26 7.52 -77.55
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 2.62 3.18 1.54 1.71 0.88 1.83 0.12 0.74 1.63 3.94 0.09
Invested Capital Turnover		 0.11 0.10 0.22 1.68 1.44 1.80 2.60 13.59 10.31 6.38 3.86
Increase / (Decrease) in Invested Capital		 2.92 0.56 -1.64 0.17 -0.83 0.95 -1.70 0.62 0.89 2.31 -3.86
Enterprise Value (EV)		 45 83 47 37 42 27 52 52 44 52 55
Market Capitalization		 43 79 40 34 37 29 56 55 50 57 59
Book Value per Share		 $0.00 ($0.01) ($0.04) ($0.01) ($0.01) $0.02 $0.02 $0.02 $0.02 $0.03 $0.01
Tangible Book Value per Share		 $0.00 ($0.01) ($0.04) ($0.03) ($0.02) $0.01 $0.02 $0.02 $0.02 $0.03 $0.01
Total Capital		 4.39 5.09 3.38 2.36 2.88 2.61 1.61 3.28 4.79 7.50 3.86
Total Debt		 3.25 5.86 6.79 3.49 5.06 2.84 0.68 1.27 0.59 1.44 2.34
Total Long-Term Debt		 3.25 5.25 1.54 1.29 0.00 0.51 0.37 1.27 0.29 0.89 0.86
Net Debt		 1.48 3.95 5.80 2.83 4.41 2.06 -0.33 -0.61 -2.97 -2.12 -1.55
Capital Expenditures (CapEx)		 0.00 0.06 0.03 0.06 0.04 0.02 0.02 0.27 0.48 1.24 -0.44
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.33 -0.44 1.20 0.00 1.12 -0.42 -0.22 -0.27 0.41 1.49 -2.35
Debt-free Net Working Capital (DFNWC)		 1.43 1.47 2.19 0.66 1.78 0.29 0.74 1.58 3.95 5.04 1.53
Net Working Capital (NWC)		 1.43 0.86 -3.06 -1.54 -3.29 -2.04 0.43 1.58 3.65 4.49 0.05
Net Nonoperating Expense (NNE)		 2.15 4.62 5.42 6.21 6.75 4.39 2.15 1.36 1.44 1.32 4.79
Net Nonoperating Obligations (NNO)		 1.48 3.95 4.95 2.83 3.06 2.06 -0.81 -1.27 -2.57 -2.12 -1.44
Total Depreciation and Amortization (D&A)		 0.82 2.63 3.09 2.82 3.44 1.68 0.14 0.06 0.28 0.26 0.60
Debt-free, Cash-free Net Working Capital to Revenue		 -260.19% -155.89% 232.75% 0.15% 60.18% -17.35% -8.73% -4.66% 3.38% 8.40% -30.32%
Debt-free Net Working Capital to Revenue		 1,121.76% 523.62% 424.61% 24.16% 95.38% 12.09% 29.28% 26.80% 32.31% 28.35% 19.69%
Net Working Capital to Revenue		 1,121.76% 306.62% -592.64% -56.31% -176.73% -83.84% 16.87% 26.80% 29.86% 25.25% 0.66%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.06) ($0.09) ($0.10) ($0.09) ($0.08) ($0.05) ($0.03) ($0.02) ($0.02) ($0.01) ($0.04)
Adjusted Weighted Average Basic Shares Outstanding		 84.11M 87.94M 98.94M 122.00M 152.09M 195.99M 247.20M 268.30M 285.96M 298.12M 306.95M
Adjusted Diluted Earnings per Share		 ($0.06) ($0.09) ($0.10) ($0.09) ($0.08) ($0.05) ($0.03) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 86.27M 94.95M 105.11M 143.10M 172.34M 238.78M 262.72M 283.19M 295.55M 301.30M 319.75M
Adjusted Basic & Diluted Earnings per Share		 ($0.06) ($0.09) ($0.10) ($0.09) ($0.08) ($0.05) ($0.03) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 86.27M 94.95M 105.11M 143.10M 172.34M 238.78M 262.72M 283.19M 295.55M 301.30M 319.75M
Normalized Net Operating Profit after Tax (NOPAT)		 -2.93 -3.45 -4.13 -4.49 -4.69 -5.31 -4.51 -3.64 -2.93 -3.03 -10
Normalized NOPAT Margin		 -2,294.24% -1,228.86% -799.85% -164.53% -251.86% -218.26% -178.00% -61.78% -23.96% -17.05% -133.79%
Pre Tax Income Margin		 -3,979.43% -2,872.35% -1,987.60% -349.23% -618.11% -403.41% -272.38% -88.29% -38.00% -24.45% -195.61%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -4.10 -1.58 -1.49 -1.39 -1.29 -3.15 -28.46 -97.02 0.00 -60.76 -27.50
NOPAT to Interest Expense		 -2.94 -1.10 -1.07 -0.99 -0.93 -2.24 -20.28 -71.19 0.00 -42.70 -19.26
EBIT Less CapEx to Interest Expense		 -4.10 -1.60 -1.50 -1.40 -1.30 -3.16 -28.55 -102.13 0.00 -78.15 -26.69
NOPAT Less CapEx to Interest Expense		 -2.94 -1.12 -1.08 -1.01 -0.94 -2.25 -20.37 -76.30 0.00 -60.09 -18.45
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% -0.42% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% -0.42% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for BioLargo

This table displays calculated financial ratios and metrics derived from BioLargo's official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 289,500,358.00 295,552,937.00 296,839,523.00 300,619,329.00 301,179,163.00 301,303,131.00 302,840,771.00 308,989,058.00 313,762,657.00 319,750,855.00 320,883,262.00
DEI Adjusted Shares Outstanding		 289,500,358.00 295,552,937.00 296,839,523.00 300,619,329.00 301,179,163.00 301,303,131.00 302,840,771.00 308,989,058.00 313,762,657.00 319,750,855.00 320,883,262.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.02 -0.01 -0.01 -0.01
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 108.49% 27.20% 246.75% 62.84% -16.38% -31.32% -44.62% -74.65% -83.14% -65.89% -55.06%
EBITDA Growth		 32.48% -71.50% 52.55% 32.03% -77.45% -141.41% -140.63% -608.76% -130.03% -78.77% -110.76%
EBIT Growth		 27.19% -71.08% 50.10% 30.97% -68.67% -143.25% -131.62% -576.72% -134.29% -77.21% -106.88%
NOPAT Growth		 28.88% -59.96% 42.91% 30.97% -60.58% -144.04% -102.47% -576.72% -148.05% -72.07% -106.88%
Net Income Growth		 27.56% -56.88% 52.03% 29.71% -69.80% -147.87% -141.28% -583.40% -139.15% -77.25% -112.54%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 -104.88% 1,218.60% 89.82% -93.78% -95,700.00% -480.46% -1,302.65% -70.31% 17.01% -59.40% -44.29%
Free Cash Flow Firm Growth		 1.01% -412.20% 77.45% 65.79% -116.14% -256.74% -1,257.98% -343.15% 130.42% 130.76% 147.10%
Invested Capital Growth		 119.68% 114.65% -20.10% 11.94% 141.78% 245.31% 291.56% -44.80% -97.82% -91.52% -107.03%
Revenue Q/Q Growth		 63.55% 8.92% 5.34% -13.22% -16.02% -10.54% -15.05% -60.28% -44.15% 81.01% 11.93%
EBITDA Q/Q Growth		 36.55% 22.11% 3.19% -42.06% -65.66% -5.96% 3.50% -318.43% 46.23% 17.65% -13.77%
EBIT Q/Q Growth		 33.96% 24.83% -1.97% -36.38% -61.36% -8.41% 2.91% -298.45% 44.14% 18.00% -13.35%
NOPAT Q/Q Growth		 34.48% 24.23% -16.64% -19.21% -52.40% -15.15% 3.22% -298.45% 44.14% 20.12% -16.35%
Net Income Q/Q Growth		 32.36% 24.02% -0.65% -35.90% -63.40% -10.91% 2.03% -284.91% 42.82% 17.79% -17.47%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 99.76% 24,150.00% -131.39% -972.85% -18.27% 4.49% -15.74% -30.26% 42.37% -83.46% -4.77%
Free Cash Flow Firm Q/Q Growth		 42.26% 29.62% 69.94% -180.03% -264.83% -16.16% -14.43% 8.62% 125.04% 17.46% 75.21%
Invested Capital Q/Q Growth		 -3.15% -32.58% 3.46% 65.70% 109.18% -3.70% 17.31% -76.64% -91.73% 274.42% -197.21%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 47.83% 47.18% 42.62% 39.58% 47.84% 45.52% 51.17% 33.73% 20.29% 41.08% 54.09%
EBITDA Margin		 -21.21% -15.17% -13.94% -22.82% -45.02% -53.32% -60.57% -638.08% -614.29% -279.46% -284.05%
Operating Margin		 -23.04% -16.03% -17.75% -24.39% -44.25% -56.96% -64.89% -650.95% -651.14% -287.35% -298.72%
EBIT Margin		 -23.23% -16.03% -15.52% -24.39% -46.85% -56.78% -64.89% -650.95% -651.14% -294.98% -298.72%
Profit (Net Income) Margin		 -23.34% -16.28% -15.56% -24.36% -47.40% -58.76% -67.77% -656.75% -672.40% -305.38% -320.51%
Tax Burden Percent		 98.65% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 101.87% 101.57% 100.26% 99.91% 101.17% 103.50% 104.44% 100.89% 103.27% 103.53% 107.30%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -166.34% -184.54% -163.24% -177.01% -197.72% -265.40% -228.39% -3,367.01% -1,757.76% -548.28% -412.45%
ROIC Less NNEP Spread (ROIC-NNEP)		 -149.93% -177.75% -159.02% -166.83% -172.11% -242.28% -208.89% -3,296.28% -1,682.69% -252.56% -756.18%
Return on Net Nonoperating Assets (RNNOA)		 92.69% 144.83% 118.38% 106.09% 78.64% 126.47% 111.21% 2,248.18% 788.97% 40.49% -183.71%
Return on Equity (ROE)		 -73.65% -39.71% -44.86% -70.92% -119.08% -138.93% -117.19% -1,118.83% -968.79% -507.80% -596.15%
Cash Return on Invested Capital (CROIC)		 -345.19% -495.74% -207.18% -157.31% -191.80% -265.51% -277.49% -538.90% -324.98% -382.07% 0.00%
Operating Return on Assets (OROA)		 -43.49% -25.79% -31.19% -53.53% -89.00% -90.97% -80.86% -723.67% -537.19% -173.53% -127.23%
Return on Assets (ROA)		 -43.71% -26.20% -31.27% -53.48% -90.04% -94.15% -84.45% -730.12% -554.74% -179.65% -136.51%
Return on Common Equity (ROCE)		 -138.95% -66.18% -59.89% -113.25% -182.19% -213.38% -144.69% -1,844.07% -1,647.40% -973.02% -1,235.81%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -60.74% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.70 -0.53 -0.62 -0.74 -1.13 -1.30 -1.26 -5.03 -2.81 -2.24 -2.61
NOPAT Margin		 -16.13% -11.22% -12.43% -17.07% -30.98% -39.87% -45.42% -455.67% -455.80% -201.15% -209.10%
Net Nonoperating Expense Percent (NNEP)		 -16.41% -6.80% -4.21% -10.18% -25.61% -23.11% -19.51% -70.73% -75.07% -295.73% 343.73%
Return On Investment Capital (ROIC_SIMPLE)		 -14.71% -9.43% -8.85% -10.45% -15.10% -17.13% -13.68% -77.32% -72.70% -51.70% -83.59%
Cost of Revenue to Revenue		 52.17% 52.82% 57.38% 60.42% 52.16% 54.48% 48.83% 66.27% 79.71% 58.92% 45.91%
SG&A Expenses to Revenue		 51.88% 46.74% 47.95% 48.10% 70.61% 77.15% 96.80% 279.96% 557.31% 247.09% 265.63%
R&D to Revenue		 9.98% 16.47% 12.43% 15.86% 21.48% 24.20% 19.27% 55.76% 105.84% 81.35% 87.18%
Operating Expenses to Revenue		 70.87% 63.21% 60.37% 63.96% 92.09% 102.48% 116.06% 684.68% 671.43% 328.43% 352.80%
Earnings before Interest and Taxes (EBIT)		 -1.02 -0.76 -0.78 -1.06 -1.71 -1.86 -1.80 -7.18 -4.01 -3.29 -3.73
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -0.93 -0.72 -0.70 -0.99 -1.65 -1.74 -1.68 -7.04 -3.78 -3.12 -3.55
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 7.25 12.98 12.77 8.23 6.47 11.00 7.26 8.08 14.58 29.11 0.00
Price to Tangible Book Value (P/TBV)		 7.25 12.98 12.77 8.23 6.47 11.00 7.26 8.08 14.58 29.11 0.00
Price to Revenue (P/Rev)		 4.06 7.95 4.56 3.82 3.22 5.14 4.52 4.92 7.59 9.26 9.14
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 27.01 89.67 64.13 34.61 13.28 21.39 13.59 46.64 637.99 156.56 0.00
Enterprise Value to Revenue (EV/Rev)		 3.60 7.44 4.34 3.53 2.94 4.98 4.31 4.49 7.07 8.98 9.82
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.14 0.10 0.20 0.19 0.24 0.50 0.52 1.02 1.53 -24.20 -2.14
Long-Term Debt to Equity		 0.07 0.06 0.20 0.19 0.15 0.34 0.34 0.67 0.56 -16.11 -1.62
Financial Leverage		 -0.62 -0.81 -0.74 -0.64 -0.46 -0.52 -0.53 -0.68 -0.47 -0.16 0.24
Leverage Ratio		 2.10 1.89 1.67 1.72 1.82 1.99 1.89 2.11 2.48 3.89 5.76
Compound Leverage Factor		 2.14 1.92 1.68 1.72 1.85 2.06 1.97 2.13 2.56 4.03 6.18
Debt to Total Capital		 12.29% 9.14% 16.32% 15.82% 19.20% 33.12% 34.26% 50.54% 60.49% 104.31% 187.44%
Short-Term Debt to Total Capital		 6.26% 4.13% 0.00% 0.00% 7.36% 10.67% 12.11% 17.17% 38.27% 34.88% 45.42%
Long-Term Debt to Total Capital		 6.03% 5.01% 16.32% 15.82% 11.83% 22.45% 22.15% 33.37% 22.22% 69.43% 142.02%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 -55.15% -52.37% -1.56% -36.54% -37.29% -33.10% -29.24% -51.77% -65.15% -45.48% -28.12%
Common Equity to Total Capital		 142.85% 143.22% 85.24% 120.72% 118.09% 99.97% 94.98% 101.23% 104.66% 41.17% -59.32%
Debt to EBITDA		 -0.14 -0.11 -0.30 -0.34 -0.35 -0.50 -0.52 -0.27 -0.16 -0.29 -0.33
Net Debt to EBITDA		 0.69 0.84 0.95 0.83 0.52 0.01 0.06 0.11 0.11 -0.03 -0.21
Long-Term Debt to EBITDA		 -0.07 -0.06 -0.30 -0.34 -0.22 -0.34 -0.34 -0.18 -0.06 -0.19 -0.25
Debt to NOPAT		 -0.18 -0.15 -0.39 -0.43 -0.47 -0.66 -0.71 -0.38 -0.22 -0.40 -0.46
Net Debt to NOPAT		 0.93 1.13 1.24 1.06 0.70 0.02 0.08 0.15 0.15 -0.04 -0.29
Long-Term Debt to NOPAT		 -0.09 -0.08 -0.39 -0.43 -0.29 -0.45 -0.46 -0.25 -0.08 -0.27 -0.35
Altman Z-Score		 -16.04 -5.95 -7.64 -8.44 -10.54 -9.39 -9.95 -19.99 -22.61 -23.71 -34.00
Noncontrolling Interest Sharing Ratio		 -88.67% -66.67% -33.50% -59.69% -53.00% -53.58% -23.47% -64.82% -70.05% -91.62% -107.30%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.35 2.11 2.36 2.31 2.70 2.14 2.25 1.67 1.01 1.10 0.73
Quick Ratio		 2.27 2.00 2.28 2.22 2.54 2.01 2.13 1.54 0.89 0.98 0.61
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -1.59 -1.12 -0.34 -0.94 -3.44 -4.00 -4.58 -4.18 1.05 1.23 2.16
Operating Cash Flow to CapEx		 -1.37% 55.74% -42.18% -4,153.85% 0.00% 0.00% 0.00% 0.00% -12,230.77% -9,115.63% -1,910.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 -72.59 0.00 -43.00 0.00 -29.04 0.00 6.54 7.56
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 -124.62 0.00 -19.68 0.00 -19.16 0.00 -15.52 -10.72
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 -127.62 0.00 -19.68 0.00 -17.38 0.00 -15.69 -11.28
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 1.87 1.61 2.01 2.20 1.90 1.60 1.25 1.11 0.83 0.59 0.43
Accounts Receivable Turnover		 6.65 6.88 10.71 7.93 6.15 4.88 7.32 5.44 4.11 2.27 3.32
Inventory Turnover		 44.51 34.50 58.80 57.22 41.10 29.65 24.75 17.85 13.62 9.79 6.56
Fixed Asset Turnover		 25.77 14.09 14.29 15.37 14.79 10.22 8.09 6.22 4.59 3.36 2.38
Accounts Payable Turnover		 3.37 2.98 3.82 3.89 6.01 3.50 1.92 1.58 1.89 1.06 0.60
Days Sales Outstanding (DSO)		 54.85 53.08 34.09 46.00 59.33 74.86 49.86 67.07 88.91 160.61 109.94
Days Inventory Outstanding (DIO)		 8.20 10.58 6.21 6.38 8.88 12.31 14.75 20.45 26.80 37.29 55.60
Days Payable Outstanding (DPO)		 108.31 122.42 95.53 93.71 60.69 104.30 189.97 231.24 193.26 344.13 607.79
Cash Conversion Cycle (CCC)		 -45.26 -58.76 -55.24 -41.33 7.52 -17.14 -125.36 -143.72 -77.55 -146.23 -442.25
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 1.63 1.10 1.14 1.88 3.94 3.80 4.45 1.04 0.09 0.32 -0.31
Invested Capital Turnover		 10.31 16.45 13.14 10.37 6.38 6.66 5.03 7.39 3.86 2.73 1.97
Increase / (Decrease) in Invested Capital		 0.89 0.59 -0.29 0.20 2.31 2.70 3.32 -0.84 -3.86 -3.47 -4.77
Enterprise Value (EV)		 44 99 73 65 52 81 60 49 55 50 40
Market Capitalization		 50 105 77 71 57 84 64 53 59 52 37
Book Value per Share		 $0.02 $0.03 $0.02 $0.03 $0.03 $0.03 $0.03 $0.02 $0.01 $0.01 ($0.01)
Tangible Book Value per Share		 $0.02 $0.03 $0.02 $0.03 $0.03 $0.03 $0.03 $0.02 $0.01 $0.01 ($0.01)
Total Capital		 4.79 5.67 7.04 7.11 7.50 7.61 9.22 6.50 3.86 4.34 3.12
Total Debt		 0.59 0.52 1.15 1.12 1.44 2.52 3.16 3.29 2.34 4.53 5.85
Total Long-Term Debt		 0.29 0.28 1.15 1.12 0.89 1.71 2.04 2.17 0.86 3.01 4.43
Net Debt		 -2.97 -3.84 -3.63 -2.77 -2.12 -0.06 -0.34 -1.28 -1.55 0.40 3.66
Capital Expenditures (CapEx)		 0.15 0.86 0.36 0.04 -0.03 0.00 0.00 -0.26 0.01 0.03 0.16
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.41 -0.33 -0.67 0.31 1.49 2.09 2.75 -1.11 -2.35 -2.10 -2.04
Debt-free Net Working Capital (DFNWC)		 3.95 4.01 4.10 4.19 5.04 4.66 6.22 3.44 1.53 2.03 0.15
Net Working Capital (NWC)		 3.65 3.77 4.10 4.19 4.49 3.85 5.11 2.32 0.05 0.51 -1.27
Net Nonoperating Expense (NNE)		 0.32 0.24 0.16 0.32 0.60 0.62 0.62 2.22 1.33 1.16 1.39
Net Nonoperating Obligations (NNO)		 -2.57 -4.05 -4.76 -4.10 -2.12 -1.30 -1.61 -2.18 -1.44 0.51 2.42
Total Depreciation and Amortization (D&A)		 0.09 0.04 0.08 0.07 0.07 0.11 0.12 0.14 0.23 0.17 0.18
Debt-free, Cash-free Net Working Capital to Revenue		 3.38% -2.49% -3.97% 1.69% 8.40% 12.85% 19.59% -10.24% -30.32% -37.36% -49.88%
Debt-free Net Working Capital to Revenue		 32.31% 30.24% 24.37% 22.68% 28.35% 28.59% 44.29% 31.84% 19.69% 36.11% 3.72%
Net Working Capital to Revenue		 29.86% 28.47% 24.37% 22.68% 25.25% 23.61% 36.35% 21.51% 0.66% 9.14% -31.01%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($0.01) $0.00 $0.00 ($0.02) ($0.01) ($0.01) ($0.01)
Adjusted Weighted Average Basic Shares Outstanding		 285.96M 294.31M 296.44M 300.49M 298.12M 301.27M 303.20M 308.97M 306.95M 318.70M 320.98M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 295.55M 296.84M 300.62M 301.18M 301.30M 302.84M 308.99M 313.76M 319.75M 320.88M 328.73M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 295.55M 296.84M 300.62M 301.18M 301.30M 302.84M 308.99M 313.76M 319.75M 320.88M 328.73M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.70 -0.53 -0.62 -0.74 -1.13 -1.30 -1.26 -5.03 -2.81 -2.24 -2.61
Normalized NOPAT Margin		 -16.13% -11.22% -12.43% -17.07% -30.98% -39.87% -45.42% -455.67% -455.80% -201.15% -209.10%
Pre Tax Income Margin		 -23.66% -16.28% -15.56% -24.36% -47.40% -58.76% -67.77% -656.75% -672.40% -305.38% -320.51%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 -81.62 0.00 -19.96 0.00 -49.86 0.00 -17.49 -13.08
NOPAT to Interest Expense		 0.00 0.00 0.00 -57.13 0.00 -14.02 0.00 -34.90 0.00 -11.93 -9.16
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 -84.62 0.00 -19.96 0.00 -48.08 0.00 -17.66 -13.64
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 -60.13 0.00 -14.02 0.00 -33.13 0.00 -12.10 -9.72
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

BioLargo’s latest financial statements show a company with improving gross profitability but continued substantial operating losses and reliance on outside financing. The most recent quarter, Q2 2026, also reflects a sharp reduction in liquidity compared with the prior quarter and a balance sheet that has moved into a negative-equity position.

  • Revenue improved sequentially. Q2 2026 revenue increased to $1.25 million from $1.12 million in Q1 2026, a gain of approximately 12%. This was a modest improvement, although revenue remained well below the $2.78 million reported in Q2 2025 and $5.01 million in Q2 2024.
  • Gross margin strengthened. Gross profit rose to $675,000 in Q2 2026 from $458,000 in Q1 2026. The gross margin improved to approximately 54%, compared with 41% in Q1 2026 and 51% in the restated Q2 2025 results.
  • Accounts receivable and inventory were relatively contained. Accounts receivable was $724,000 and inventory was $303,000 at June 30, 2026, both well below the elevated receivable and inventory balances reported during parts of 2024 and 2025. This may reduce working-capital pressure, although the lower receivables also reflect the company’s weaker sales level.
  • BioLargo continued to access financing. During Q2 2026, the company generated $1.28 million from financing activities, including $1.0 million of debt issuance and $391,000 from common equity issuance. Access to capital has helped fund operations despite ongoing cash losses.
  • Research and development spending remains significant. R&D expense increased to $1.09 million in Q2 2026 from $907,000 in Q1 2026. Continued investment could support future product development, but it is not yet producing operating profitability.
  • Capital spending increased. Purchases of property, plant and equipment rose to $160,000 in Q2 2026 from $32,000 in Q1. This could indicate investment in production or operating capacity, but it also adds to the company’s cash requirements while internal cash generation remains negative.
  • Operating losses remain substantial. BioLargo reported a Q2 2026 operating loss of $3.73 million and a net loss of $4.00 million. Selling, general and administrative expense was $3.32 million, while R&D expense was $1.09 million, together greatly exceeding the company’s $675,000 gross profit.
  • Cash burn accelerated. Net cash used in operating activities was $3.06 million in Q2 2026, compared with $2.92 million in Q1 2026 and $2.12 million in the restated Q2 2025 period. Cash and equivalents fell to $2.19 million from $4.12 million at the end of Q1, even after new debt and equity financing.
  • Liquidity is weak relative to current obligations. At June 30, 2026, current assets totaled $3.50 million versus current liabilities of $4.77 million, implying a current ratio of approximately 0.73. Accounts payable alone reached $4.12 million, creating pressure on the company to raise capital, collect receivables or improve cash generation.
  • Leverage and shareholder dilution are increasing. Total liabilities rose to $9.40 million in Q2 2026 from $5.92 million in Q3 2025, while long-term debt and capital lease obligations totaled approximately $4.43 million. Weighted-average basic shares increased to roughly 321.0 million in Q2 2026 from 294.3 million in Q1 2024, reflecting the company’s ongoing use of equity financing.
  • Book value has deteriorated sharply. Total equity and noncontrolling interests were negative $2.73 million at June 30, 2026, compared with positive $5.09 million in Q1 2024. Retained earnings were negative $166.3 million, highlighting the cumulative impact of long-term operating losses.

Overall, BioLargo’s higher Q2 2026 gross margin and sequential revenue improvement are encouraging, but they have not yet translated into a sustainable operating model. The company continues to consume several million dollars of cash each quarter, carries significant short- and long-term obligations, and has financed operations through debt and common-stock issuance. Retail investors should monitor revenue growth, operating expense control, accounts payable, cash balances and the company’s ability to raise additional capital without excessive dilution.

11/13/26 12:22 PM ETAI Generated. May Contain Errors.

BioLargo Financials - Frequently Asked Questions

According to the most recent income statement we have on file, BioLargo's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Over the last 10 years, BioLargo's net income changed from -$5.08 million in 2015 to -$15.19 million in 2025, a change of -199.2%.

BioLargo's total operating income in 2025 was -$14.86 million, based on the following breakdown:
  • Total Gross Profit: $3.41 million
  • Total Operating Expenses: $18.26 million

Over the last 10 years, BioLargo's total revenue changed from $127.58 thousand in 2015 to $7.77 million in 2025, a change of 5,986.3%.

In the past 11 quarters, BioLargo's cash and equivalents has ranged from $2.19 million in Q2 2026 to $4.77 million in Q2 2024, and is currently $2.19 million as of their latest financial filing in Q2 2026.

BioLargo had total debt of $2.34 million at the end of 2025, a 62.3% increase from 2024, and a 28.0% decrease since 2015.

Over the last 10 years, BioLargo's book value per share changed from 0.00 in 2015 to 0.01 in 2025, a change of 207.1%.


Related Companies

Financial statements for NASDAQ:BLGO last updated on 8/15/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...
Base Camp Trading | Sponsoredtc pixel
Trump’s EO to send this $5 stock ripping higher…?
President Trump's December executive order declared space a national security and economic priority, fueling a...
Traders Agency | Sponsoredtc pixel
Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...
Behind the Markets | Sponsoredtc pixel
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
Uranium Mine Flood That Sparked a 2006 Price Surge Returns
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...
Digest Publishing | Sponsoredtc pixel
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...
Weiss Ratings | Sponsoredtc pixel
My next big call (under $1)
17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...
Crypto 101 Media | Sponsoredtc pixel